Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis

Bibliography

• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. for the Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, et al. for the ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37
   PubMed Web of Science ®Google Scholar
• Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warbourg did not anticipate. Cancer Cell 2012;21:297-308
   PubMed Web of Science ®Google Scholar
• Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993-8
   PubMed Web of Science ®Google Scholar
• Azuma M, Shi M, Danenberg KD, et al. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics 2007;8:1705-13
   PubMed Web of Science ®Google Scholar
• Wu XZ, Ma F, Wang XL. Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol 2010;16:4084-8
   PubMed Web of Science ®Google Scholar
• Kostakis ID, Vaiopoulos AG, Philippou A, et al. Preoperative serum lactate dehydrogenase levels in colorectal and gastric cancer: a hospital-based case-control study. Biomark Med 2013;7:131-7
   PubMed Web of Science ®Google Scholar
• Kayser G, Kassem A, Sienel W, et al. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol 2010;5:22
   Google Scholar
• Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamicin. J Clin Oncol 2012;30:3402-7
   PubMed Web of Science ®Google Scholar
• Gray MR, Martin del Campo S, Zhang X, et al. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab. Radiology 2014;270:425-34
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Prognostic and predictive role of lactate dehydrogenase 5 (LDH5) expression in colorectal cancer patients treated with PTK787/ZK222584 (Vatalanib) anti-angiogenic therapy. Clin Cancer Res 2011;17:4892-900
   PubMed Web of Science ®Google Scholar
• Bar J, Spencer S, Morgan S, et al. Correlation of lactate dehydrogenases isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: retrospective analysis of the HORZON 1 study. Clin Colorectal Cancer 2014;13:46-53
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Giampieri R, Maccaroni E, et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer 2012;106:799-804
   PubMed Web of Science ®Google Scholar
• Yin C, Jiang C, Liao F, et al. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther 2014;7:1415-22
   PubMed Web of Science ®Google Scholar
• Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012;34:43-62
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Ikeuchi S, Kitagawa Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagous. J Gastroenterol Hepatol 2007;22:2222-7
   PubMed Web of Science ®Google Scholar
• Polterauer S, Grimm C, Seebacher V, et al. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 2009;14:979-85
   PubMed Web of Science ®Google Scholar
• Sun ZQ, Han XN, Wang HJ, et al. Prognostic significance of preoperative fibrinogen in patients with colon cancer. World J Gastroenterol 2014;20:8583-91
   PubMed Web of Science ®Google Scholar
• Laurens N, Koolwijk P, De Maat PM. Fibrin structure and wound healing. J Thromb Haemost 2006;4:932-9
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao M, Jin B, et al. Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen. BMC Cancer 2012;12:330
   PubMed Web of Science ®Google Scholar
• Diaz R, Aparicio J, Girones R, et al. Analysis of prognostic factors and applicability of Kohne’s prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy. Clin Colorectal Cancer 2005;5:197-202
   PubMedGoogle Scholar
• Lin JT, Wang WS, Yen CC, et al. Outcome of colorectal carcinoma in patients under 40 years of age. J Gastroenterol Hepatol 2005;20:900-5
   PubMed Web of Science ®Google Scholar
• Faloppi L, Scartozzi M, Bianconi M, et al. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer 2014;14:110
   PubMed Web of Science ®Google Scholar
• Ghanim B, Hoda MA, Klikovits T, et al. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. Br J Cancer 2014;110:984-90
   PubMed Web of Science ®Google Scholar
• Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52
   PubMed Web of Science ®Google Scholar